We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Rare disease biotech Eidos Therapeutics priced its IPO at $17 a share, hauling in about $106.3 million to push its treatment for transthyretin (TTR) amyloidosis through the clinic.